摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

methyl 2-(2-(3,4-dihydro-2H-pyran-6-yl)phenyl)acetate | 1375014-88-2

中文名称
——
中文别名
——
英文名称
methyl 2-(2-(3,4-dihydro-2H-pyran-6-yl)phenyl)acetate
英文别名
methyl 2-[2-(3,4-dihydro-2H-pyran-6-yl)phenyl]acetate
methyl 2-(2-(3,4-dihydro-2H-pyran-6-yl)phenyl)acetate化学式
CAS
1375014-88-2
化学式
C14H16O3
mdl
——
分子量
232.279
InChiKey
VBJUIIUFKWLSEZ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.6
  • 重原子数:
    17
  • 可旋转键数:
    4
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.36
  • 拓扑面积:
    35.5
  • 氢给体数:
    0
  • 氢受体数:
    3

反应信息

点击查看最新优质反应信息

文献信息

  • Inhibiting (α-V)(β-6) integrin
    申请人:Morphic Therapeutic, Inc.
    公开号:US11021480B2
    公开(公告)日:2021-06-01
    Disclosed are small molecule inhibitors of αvβ6 integrin, and methods of using them to treat a number of diseases and conditions.
    所公开的是αvβ6整合素的小分子抑制剂,以及用它们治疗多种疾病和病症的方法。
  • Chiral Phosphoric Acid-Catalyzed Enantioselective and Diastereoselective Spiroketalizations
    作者:Zhankui Sun、Grace A. Winschel、Alina Borovika、Pavel Nagorny
    DOI:10.1021/ja302704m
    日期:2012.5.16
    Catalytic enantioselective and diastereoselective spiroketalizations with BINOL-derived chiral phosphoric acids are reported. The chiral catalyst can override the inherent preference for the formation of thermodynamic spiroketals, and highly selective formation of nonthermodynamic spiroketals could be achieved under the reaction conditions.
  • INHIBITING (ALPHA-V)(BETA-6) INTEGRIN
    申请人:Morphic Therapeutic, Inc.
    公开号:US20200071322A1
    公开(公告)日:2020-03-05
    Disclosed are small molecule inhibitors of αvβ6 integrin, and methods of using them to treat a number of diseases and conditions.
  • [EN] INHIBITING αV β6 INTEGRIN<br/>[FR] INHIBITION DE L'INTÉGRINE ανβ6
    申请人:MORPHIC THERAPEUTIC INC
    公开号:WO2020047239A1
    公开(公告)日:2020-03-05
    Disclosed are small molecule inhibitors of ανβ6 integrin, and methods of using them to treat a number of diseases and conditions. Applicants have discovered novel ανβ6 integrin inhibitor compounds and evaluated the posession, performance and utility of represeentative examples of such compounds, both for biochemical potency (e.g., using the assay of Example 35 to evaluate fluorescence polarization assays of compounds for ανβ6 binding) and in vitro permeability properties (e.g., using the assay of Example 36 to evaluate MDCK permeability).
查看更多